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Marie Pierre Podgorniak4, Benyoussef Naïmi5, Fabien Calvo1,6, Céleste Lebbe6,7 and Samia Mourah1,4,6,8*
Abstract
Backgrounds: An elevated level of EMMPRIN in cancer tissues have been correlated with tumor invasion in
numerous cancers including oral cavity and larynx. Although EMMPRIN’s effect has been generally attributed to its
MMP inducing activity, we have previously demonstrated in breast cancer model that EMMPRIN can also enhance
invasion by upregulating uPA. In this study, the role of EMMPRIN in regulating uPA and invasion was investigated
in oral squamous cell carcinoma (OSCC) progression.
Methods: Precancerous and invasive oral tumoral tissues were used as well as the corresponding cell lines, DOK
and SCC-9 respectively. The paracrine regulation of uPA by EMMPRIN was investigated by treating culture cells
with EMMPRIN-enriched membrane vesicles. UPA expression was analyzed by qPCR and immunostaining and the
consequence on the invasion capacity was studied using modified Boyden chamber assay, in the presence or
absence of EMMPRIN blocking antibody, the uPA inhibitor amiloride or the MMP inhibitor marimastat.
Results: OSCC tumors were shown to express more EMMPRIN and uPA compared to dysplastic lesions. The
corresponding cell models, SCC-9 and DOK cells, displayed similar expression pattern. In both cell types EMMPRIN
upregulated the expression of uPA as well as that of MMP-2 and MMP-9. EMMPRIN treatment led to a significant
increase in cell invasion both in the invasive SCC-9 and in the less invasive dysplastic DOK cells, in an MMP and
uPA dependent manner.
Conclusions: Our results suggest that the upregulation of uPA contributes to EMMPRIN’s effect in promoting oral
tumor invasion.
Keywords: EMMPRIN/CD147, uPA, Oral squamous cell carcinoma, Invasion, Progression
Background
Oral squamous cancer cell carcinoma (OSCC) ranks
among the top ten most frequently cancers, and 500
000 people per year are world widely diagnosed [1].
OSCC is highly invasive with bad prognosis; despite the
recent advances in cancer therapy, the 5-year survival
rate of patients has remained at < 50% [2]. Little is
known about of the molecular events that govern OSCC
initiation, progression and metastasis. Development of
OSCC is a complex and multistep process, with trans-
formation from oral premalignant dysplastic lesion to
OSCC. Progression is generally known to involve the
intervention of proteinases [3-5]. Extracellular matrix
metalloproteinase inducer (EMMPRIN/CD147), a mem-
brane glycoprotein greatly enriched on the surface of
tumor cells, is mainly known for its ability to increase
the synthesis of MMPs in tumor cells and in the neigh-
bouring stromal cells, such as fibroblasts and endothelial
cells [6-10]. EMMPRIN has been implicated in tumor
invasion and its elevated levels in cancer tissues have
been correlated with tumor progression in numerous
malignant tumor models including tumors of the oral
cavity and larynx [11,12].
In addition to increasing invasion through proteinase
induction, EMMPRIN induces several other malignant
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properties associated with cancer. These include,
amongst others, the stimulation of cell survival signaling,
including Akt, Erk and FAK, through the increased pro-
duction of the pericellular polysaccharide hyaluronan
[13]. Also, EMMPRIN can promote angiogenesis by the
upregulation of VEGF expression as well as its main
receptor VEGFR-2 in both tumor cells and endothelial
cells [14-16]. This effect on VEGF and VEGFR-2 was
shown to be mediated by HIF-2a [17].
The role of EMMPRIN in tumor growth and invasion
was illustrated by the accelerated growth and increased
invasiveness of EMMPRIN-overexpressing human breast
cancer cells [18,19]. The increased tumor size in the
EMMPRIN overexpressing cells was associated with an
increase, in the tumors, of not only MMP-2 and MMP-
9 [18,19], but also of urokinase type plasminogen activa-
tor (uPA) levels [18]. Indeed, we have previously
reported that EMMPRIN is able to upregulate the
expression of the plasminogen activation system, includ-
ing uPA, in mammary tumor cells, further increasing its
proteolytic and invasion potential [18].
Microarray analyses of primary oral tumors have iden-
tified uPA and its receptor (uPAR) as key genes asso-
ciated with human OSCC progression [18,20,21].
Human OSCC tumors with high levels of uPA and
uPAR are more invasive, exhibit enhanced lymph node
metastasis and more frequent tumor relapse [22].
Increased expression of EMMPRIN in oral squamous
cell carcinoma has been shown to correlate with lym-
phatic metastasis and tumor progression [23]. EMM-
PRIN overexpression has been previously reported to
occur at a very early stage of oral carcinogenesis and to
play a contributing role in OSCC tumorogenesis [24].
Its role in facilitating tumor cell motility was attributed
to its ability to increase MMP production and tenascin-
C matrix deposition [25,26]. In this study using both
invasive and precancerous oral cancer cell models we
present evidence suggesting that EMMPRIN promotes
oral tumor invasion by inducing uPA expression.
Methods
Cell culture
Two cell lines representing two stages of oral tumour pro-
gression were used: DOK, a precancerous dysplastic cell
line [27] and SCC-9, an oral squamous carcinoma cell line
(Rheinwald laboratory). The cells were cultured in DMEM
with 10% fetal bovine serum (FBS) and 2mML-gluta-
mine. Chinese Hamster Ovary (CHO) cells (ATCC, Rock-
ville, MB) were cultured in DMEM/F12 (Invitrogen)
supplemented with 10% FBS and 2mML-glutamine.
Membrane preparation
CHO cells were stably transfected with a plasmid con-
taining full-lengh EMMPRIN cDNA (CHO-Emp cells)
or empty vector (CHO-Mock cells) [18]. CHO-Emp
and CHO-Mock membranes were isolated by differen-
tial centrifugation as previously described [18]. The
bioactivity of EMMPRIN-containing membranes was
verified by its ability to stimulate uPA expression in
melanoma cells [18]. The membrane vesicles obtained
from the CHO-Emp or CHO-Mock cells are referred
to as CHO-Emp mb or CHO mb respectively
throughout.
Small interfering RNA transfection
EMMPRIN small interfering RNA(siRNA) oligos
(Ambion/Applied Biosystems) or scrambled siRNA oli-
gos (25 nmol/L) were transfected into DOK and SCC-9
cells using the BLOCK-iT transfection kit and Lipofecta-
mine-2000 (Invitrogen), according to the manufacturer’s
protocol. Cells were then incubated for 24 hours prior
to the measurements of uPA mRNA by qRT-PCR and
invasion assays.
Western blotting analysis
Western blot was preformed as previously described
[14]. Membranes were immunoblotted with anti-EMM-
PRIN/CD-147 HIM6 mAb (BD Biosciences) or anti-
uPAR (R&D systems) antibodies. Proteins were visua-
lized with ECL reagent (Pierce) and their relative expres-
sion was determined by densitometry using ImageJ
software program and normalized relative to b-actin.
Gelatin and casein-plasminogen zymography
Gelatin or casein-plasminogen zymography was per-
formed as described previously [17]. Serum-free condi-
tioned media were analyzed on 10% SDS-PAGE gels
containing either 1 mg/mL gelatin for gelatinase activity
or 2 mg/mL casein (Sigma) and 10 μg/mL plasminogen
(Calbiochem) for uPA activity.
Real-time quantitative RT-PCR (qRT-PCR)
Transcript quantification for EMMPRIN, uPA, MMP-2
and MMP-9 was conducted using TaqMan technology
and standard curve quantification method. Quantitative
PCR were performed using Perfect Master Mix-Probe
(AnyGenes, France) on LightCycler system2.0 (Roche,
France) according to the manufacturer’s techniques.
Briefly, cDNAs for EMMPRIN, uPA, MMP-2 and
MMP-9 were prepared from total RNA, amplified by
RT-PCR, and cloned using TOPO II TA cloning kit
(Invitrogen). A standard curve for each transcript was
generated using serial dilutions of cloned products ran-
ging from 1 to 109 molecules/μl. The copy number of
unknown samples was calculated by setting their PCR
cycle number to the standard curve. Data were normal-
ized to the TBP (TATA-box binding protein) house-
keeping gene transcripts. Primers and probes are
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available under request. All experiments were performed
in duplicate.
Invasion and migration assays
In vitro invasion was assessed using a modified Boyden
chamber assay. SCC-9 and DOK cells (2 × 104 cells/
insert for 24-well plate) were plated onto Matrigel-
coated cell culture inserts together with either anti-
EMMPRIN antibody (20 μg/mL), non-immune IgG,
uPA inhibitor amiloride (20 nmol/L; Sigma) or the
MMP inhibitor marimastat (10 μmol/L; British Bio-
technology, Oxford, UK). Three hours later CHO-Emp
mb or CHO mb were added (20 μg/ml). After 48
hours of incubation, cells on the underside of insert
filters were fixed, stained with Diff Quik (Dade Behr-
ing) and counted under a bright-field microscope.
Migration assay was performed as above, omitting
matrigel coating.
Immunofluorescence of cultured cells
DOK and SCC-9 cells were grown in microscope slide
chambers to 50-60% confluence. CHO-Emp mb or
CHO mb were then added (20 μg/ml) and 24 hours
later, cells were washed in PBS and fixed in 4% parafor-
maldehyde for immunofluorescence detection of EMM-
PRIN or uPA. Slides were probed with mouse anti-
human EMMPRIN antibody (HIM6 BD Pharmingen) or
with goat anti human uPA antibody (American diagnos-
tica). After incubation with the corresponding secondary
antibody (Alexa 488 and 594) the slides were examined
with a laser-scanning confocal microscope (Leica Laser-
technik, Heidelberg). Cells were counterstained with
DAPI (Sigma).
Analysis of human oral squamous carcinoma and
dysplastic lesions
Tumor samples were collected from 20 patients with
oral squamous carcinoma or dysplastic tissues. Tissues
of normal oral mucosa were collected from healthy
donors attending for tooth extraction. All patients
gave their informed consent. Protocols were approved
by our institution research ethics committee. Total For-
malin-fixed paraffin-embedded (FFPE) tissue sections of
6 normal oral mucosa, 4 intra epithelial neoplasia, 8
micro-invasive OSCC and 8 invasive OSCC, were ana-
lysed for EMMPRIN and uPA expression using qRT-
PCR and immunohistochemistry assays. For immunohis-
tochemistry, FFPE sections were stained with a mouse
anti-human EMMPRIN antibody (BD-Pharmingen) and
a goat anti human uPA antibody (American diagnos-
tica). Staining was visualized using the streptavidin-bio-
tin-HRP detection method, followed by counterstaining
with Mayer’s hematoxylin. Three-amino-9-ethyl-carba-
zole (Sigma-Aldrich, France) was used as the
chromogen. For transcript quantification levels, RNA
was extracted using TRIzol reagent (Invitrogen). First-
strand cDNA was synthesized using the High-Capacity
cDNA Archive Kit (Applied-Biosystems). Transcript
levels were measured in each tissue by qPCR using Per-
fect Master Mix-Probe (AnyGenes, France) on LightCy-
cler 2.0 System (Roche). The expression levels of
interesting transcripts were normalized to the house-
keeping TATA-box binding protein (TBP) gene tran-
scripts. All experiments were performed in duplicates
and Spearman’s rank correlation was used to evaluate
the association between mRNA levels in oral dysplastic,
micro-invasive and invasive tumor tissues.
Statistical analysis
Data are expressed as mean F SD. Mann-Whitney and
Student’s t tests were used to compare differences
between groups in various experiments.
Results
EMMPRIN and uPA expression is increased with oral
tumor progression
The expression of EMMPRIN and uPA was examined in
a tumor series from 20 patients with dysplasctic (4)
micro-invasive (8) or invasive lesions (8) and compared
with to their expression in normal oral mucosa (6).
QRT-PCR analysis has shown that both EMMPRIN and
uPA transcripts were proportionally increased with the
invasive stage of the tumors (Figure 1A). An average
increase of 2.5 fold for EMMPRIN and 11 fold for uPA
can be noted between the dysplastic and the invasive
stage, while their levels in normal mucosa were the
lowest, displaying 5 fold less EMMPRIN and 3 fold
less uPA than in the dysplastic lesions.
EMMPRIN and uPA expression was also evaluated by
immunohistochemical analysis of tumors obtained from
OSCC patients. Figure 1B presents a representative
staining pattern showing more intense staining of both
EMMPRIN and uPA in burgeoning (micro-invasive) and
invasive tumor lesions than dysplastic lesions. Moreover,
EMMPRIN and uPA staining was localized in the same
areas within the tissue.
EMMPRIN regulates uPA in oral dysplastic DOK and
tumoral SCC-9 cell lines
The association of both EMMPRIN and uPA transcript
with oral tumor progression and their colocalization
within tumor tissues prompted us to look for a regula-
tion of uPA by EMMPRIN. For that, two cell lines,
DOK and SCC-9, representing the dysplastic and the
invasive stages respectively were studied. These two cell
models present a differential expression of EMMPRIN
(Figure 2), with SCC-9 showing higher transcript and
protein levels of EMMPRIN compared to DOK cells,
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evaluated by quantitative RT-PCR, western blot and
Immunofluorescence analyses.
The role of EMMPRIN in the regulation of uPA pro-
duction in these two cell lines was investigated by treat-
ing the cells with exogenously added EMMPRIN.
EMMPRIN contained within membrane vesicles was
obtained from CHO cells previously transfected with
EMMPRIN full length cDNA. The incubation of DOK
and SCC-9 cells with 20 μg/ml of EMMPRIN-containing
membranes (designated CHO-Emp) increased uPA pro-
tease activity (by 40% for DOK and 26% for SCC-9) and
RNA levels (5 fold for DOK and SCC- 9) when mea-
sured by casein-plasminogen zymography and qRT-PCR
respectively, whereas those prepared from mock-trans-
fected CHO cells (CHO) had no effect (Figure 3A). This
was also accompanied by an increase in MMP-2 and
MMP-9 measured by qRT-PCR and gelatine zymogra-
phy. TIMP-1 which was shown not to be an EMMPRIN
target [28] was used here as negative control showing
no regulation by EMMPRIN in our cell models (Figure
3Ac). The regulation of uPA by EMMPRIN in both cell
lines was confirmed by immunofluorescence analysis
(Figure 3Ad).
To evaluate the specificity of EMMPRIN’s effects,
blocking anti-EMMPRIN antibody was added with the
EMMPRIN containing membranes and the effect on
uPA production was examined by zymography. As
shown in Figure 3B, anti-EMMPRIN antibody (20 μg/
mL), but not IgG control, blocked EMMPRIN’s effect
on uPA in both DOK and SCC-9 cells. A down-regula-
tion of MMP-2 and -9 activities was also observed (data
not shown).
The regulation of uPA by EMMPRIN was also investi-
gated by inhibiting endogenous EMMPRIN expression
using RNA interference strategy. EMMPRIN siRNA
transfection of DOK and SCC-9 cells showed a signifi-
cant reduction in the transcript level of uPA (Figure
3C).
Hence, EMMPRIN regulated uPA in both the dysplas-
tic and the invasive tumor cell lines, suggesting a regula-
tory mechanism involved even at the early
tumorogenesis stages
Figure 1 EMMPRIN and uPA expression in human oral dysplastic and squamous carcinoma lesions. A- EMMPRIN and uPA mRNA
expression in oral dysplastic and tumor tissues. RNA was extracted from formalin-fixed paraffin-embedded tissue sections of 6 normal oral
mucosa (Normal), 4 intra epithelial neoplasia (Dysplastic), 8 micro-invasive OSCC and 8 invasive OSCC, and were analysed for EMMPRIN and
uPA expression using qRT-PCR assays. * denotes significant difference with p < 0.05. B- Immunohistochemical staining of EMMPRIN and uPA in
sections of human oral dysplastic, micro-invasive and invasive squamous carcinoma lesions. Tissue sections from patients with oral dysplastic
lesions (OIN), micro-invasive lesions (Micro-inv) and invasive oral squamous carcinoma lesions (INV) lesion sections were subjected to single-
labeled immunohistochemistry using mouse anti-human EMMPRIN mAb or goat anti-human uPA Ab and counterstained with HES. EMMPRIN
and uPA were colocalized, their staining was heterogeneous with particularly high staining at some regions. Staining was more intense in the
tumor sections.
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EMMPRIN promotes in vitro cell invasion in oral tumor
progression model
EMMPRIN has already been implicated in tumor cell
invasion [10,29]. This was confirmed in our in vitro
experiments using the Matrigel invasion assay, showing
an increase in the invasive capacity of both cells, DOK
and SCC-9, which was abolished by the presence of 20
μg/mL EMMPRIN blocking antibody. The rate of inva-
sion of SCC-9, the more aggressive cell type, was greater
than that of DOK. In addition, EMMPRIN increased
invasion in both cell types by approximately 3 fold, pro-
gressing the invasiveness of the dysplastic cells DOK to
that of the invasive SCC-9 cells (Figure 4A). It is inter-
esting that EMMPRIN antibody also inhibited the inva-
sion of control cells (treated with CHO-Mock),
suggesting that endogenously produced EMMPRIN also
contributes to invasion. Cell invasion was also reduced
in both cell lines after inhibition of EMMPRIN by
siRNA (Figure 4B).
EMMPRIN also had a more significant effect on the
Invasion Indices (calculated as percent of invaded cells
relative to migrated cells) of SCC-9 compared to DOK.
This emphasizes the protease inducing function of
EMMPRIN in the invasion process (Figure 4C).
Since EMMPRIN is mostly known to upregulate
MMPs, we investigated the relative contribution of the
uPA and MMP systems to the invasion capacity of both
cell lines. For that, we used 20 nmol/L amiloride (for
uPA inhibition) and 10 μmol/L marimastat (for a global
MMP inhibition) which were added alone or in combi-
nation. As expected, an inhibition of invasion was
observed in both cell lines in the presence of either
amiloride or marimastat, the inhibition was greater
when the inhibitors were used in combination. However,
EMMPRIN treatment did not restore invasion in any of
these conditions (Figure 4D). These results suggest that
EMMPRIN regulates in vitro oral tumor cell invasion
through both uPA and MMP activities.
Discussion
EMMPRIN is widely distributed in many human and
mammalian cells, with notably high expression in some
of solids cancers including oral squamous cell carci-
noma. It’s over-expression is associated with malignancy
and ⁄ or poor prognosis in many tumor types, and sev-
eral studies suggest that EMMPRIN is an important fac-
tor which contributes to oral squamous cell carcinoma
growth, invasion, and metastasis [30]. EMMPRIN
increased expression was observed at a very early stage
of oral carcinogenesis. Indeed, it was shown to increase
in dysplastic leukoplakias spreading to more superficial
layers, and its expression levels correlated significantly
with the degree of dysplasia [24].
The functional importance of EMMPRIN during
tumor progression has been related mainly to its ability
to promote tumor cell invasion by stimulating MMP
and VEGF cytokine production expression [31]. We
have previously showed that EMMPRIN can also
Figure 2 EMMPRIN expression of dysplastic and tumor cell lines. A, EMMPRIN expression was evaluated by western blotting analysis of 10
μg of DOK and SCC-9 cell lysates (b-actin was used as loading control). Representative blot is shown. EMMPRIN transcripts in DOK and SCC-9
cells were quantified using quantitative RT-PCR. Columns represent average values from at least three independent experiments carried out in
triplicate; bars, SD. * denotes significant difference with p < 0.05. B, Immunofluorescence staining for EMMPRIN in DOK and SCC-9 cells. Cells
were counterstained with DAPI (×400). EMMPRIN staining was stronger in the SCC-9 tumor cells compared to the Dysplastic DOK cells.
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stimulate the serine uPA proteinase system in breast
cancer, thus representing an additional degradation
pathway enhancing its tumor invasion potential [18].
Our results showing that EMMPRIN also regulated
uPA in oral tumors and colocalized with it in the
tumoral tissues where both EMMPRIN and uPA were
overexpressed suggest that this pathway may play an
important role in oral tumor progression. In addition,
amiloride, a uPA inhibitor significantly reduced inva-
sion of two oral tumoral cell lines used in this study,
Figure 3 EMMPRIN regulates uPA in oral dysplastic DOK and tumor SCC-9 cell lines. A, (a) CHO cells were transfected with EMMPRIN
cDNA as previously described [18]. Membranes were isolated from CHO-Emp and CHO control cells (CHO-Emp Mb and CHO Mb, respectively)
by differential centrifugation and 10 μg of membrane extract were analyzed for EMMPRIN content by immunoblotting. (b) DOK and SCC-9 cells
(80% confluence) were incubated with 20 μg/mL CHO Mb or CHO-Emp Mb in serum-free medium for 24 h and the conditioned medium was
analyzed for uPA activity using casein-plasminogen zymography and for gelatinase activities of MMP-2 and MMP-9 using gelatin zymography
(one representative zymography of three independent experiments). (c) EMMPRIN, uPA, MMP-2, MMP-9 and TIMP-1 transcripts were quantified
using quantitative RT-PCR in DOK and SCC-9 cells incubated for 24 h with CHO Mb or CHO-Emp Mb (20 μg/mL). Columns are means of gene
expression relative to TBP housekeeping gene of at least three independent experiments carried out in triplicate; bars, SD. * denotes
significant difference with p < 0.05. (d) SCC-9 and DOK cells were grown in microscope slide chambers to 50-60% confluence and incubated
with CHO Mb or CHO-Emp Mb (20 μg/mL). After 24 h, cells were immunostained for uPA using a goat anti-human antibody (green) and
counterstained with DAPI (blue). A more intense staining was observed in CHO-Emp mb treated DOK and SCC-9 cells compared to the control
CHO mb treated cells. B, SCC-9 and DOK cells were incubated with 20 μg/mL of an anti-EMMPRIN blocking antibody (Ancell, Bayport, MN) or
with a non-immune IgG antibody in serum-free medium. After 24 h incubation, conditioned medium was harvested for gelatinase and uPA
casein zymography. Columns represent average values of the densitometric quantification from at least three independent experiments carried
out in triplicate; bars, SD. * denotes significant difference with p < 0.05. C, DOK and SCC-9 cells were transfected with EMMPRIN siRNA (Emp-
siRNA) or scrambled control siRNA (Ctl siRNA) at 33 nmol/L concentration. EMMPRIN and uPA mRNA expression was evaluated by quantitative
RT-PCR analyses. Columns represent mean ± SD of relative expression to TBP housekeeping gene of at least 3 independent experiments carried
out in triplicate; bars, SD. * denotes significant difference with p < 0.05.
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Figure 4 EMMPRIN regulates invasion in oral dysplastic DOK and tumor SCC-9 cell lines in an MMP and uPA dependent manner. A, The in
vitro invasive property of DOK and SCC-9 cells incubated with CHO-Emp membranes and treated or not with an anti-EMMPRIN blocking antibody (20
μg/mL) were compared using tissue culture Transwell inserts (8-mm pore size; BD Biosciences) placed in a 24-well culture plate. Cells incubated with
CHO control or treated with an anti-IgG antibody were used as control. Cells (1 × 105) suspended in serum-free media were seeded into the upper
well of each insert onto membranes coated with growth factor-reduced Matrigel (BD Biosciences). After 48 h incubation, cells that remained in the top
compartment were removed by cotton swabs, and cells on the underside of insert filters were fixed, stained, and counted under a microscope. The
columns shown represent average values from at least three independent experiments carried out in triplicate; bars, SD. * denotes significant
difference with p < 0.05. B, DOK and SCC-9 cells were transfected with EMMPRIN siRNA or scrambled siRNA (Ctl siRNA) prior to invasion assays. The
columns represent means of three independent experiments carried out in triplicate; bars, SD. C, Invasive Indices. DOK and SCC-9 cells (1 × 105)
seeded into the upper well of tissue culture Transwell inserts coated with growth factor-reduced Matrigel (for invasion assay) or not coated (for
migration assay) were incubated with CHO or CHO-Emp membranes (Control and CHO Emp mb respectively). After 48 h of incubation, migrating or
invading cells on the underside of insert filters were fixed, stained, and counted under a microscope. Invasion Indices were calculated as percent of
the invaded cells relative to the migrated cells. The columns shown represent average values from at least three independent experiments carried out
in triplicate; bars, SD. * denotes significant difference with p < 0.05. D, Relative contribution of uPA and MMPs to the in vitro invasive property of DOK
and SCC-9 cells. Cells (1 × 105) were seeded into the upper well of matrigel coated inserts and incubated with CHO or CHO-Emp membranes. uPA
inhibitor amiloride (20 nmol/L) or MMP inhibitor marimastat (10 μmol/L) were added alone or in combination together with the membranes. After 48
h invading cells were fixed, stained, and counted. Columns represent average values from at least three independent experiments carried out in
triplicate; bars, SD. * denotes significant difference with p < 0.05.
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DOK and SCC-9, representing the dysplastic and the
invasive stages respectively. The fact that combining
amiloride with marimastat, an MMPs inhibitor, caused
a greater inhibition of EMMPRIN-mediated invasion
than either of these inhibitors alone suggests that both
pathways function in parallel and underscores EMM-
PRIN’s ability to regulate invasion through both uPA
and MMPs. EMMPRIN was shown to be without effect
on the MMP inhibitors TIMPs so the induction of
MMPs is likely to cause a direct increase in proteolysis
[28]. Whether the increase in uPA by EMMPRIN in
OSCC is accompanied by a parallel regulation of its
inhibitor PAI1 remains to be determined, but the inhi-
bition by amiloride of the increased invasion following
EMMPRIN treatment suggests a net increase in the
active uPA.
The MAP kinase P38 was implicated in the regulation
of uPA, certain MMPs and EMMPRIN itself and may
represent a common mechanism for their regulation [7].
As EMMPRIN was suggested to serve as its own recep-
tor in neighbouring cells, it is possible that constitutive
EMMPRIN acts as a receptor to the exogenous mem-
brane bound EMMPRIN, initiating signalling pathways
that result in P38 activation.
Silencing EMMPRIN in head and neck squamous
carcinoma (HNSCC) cells was shown to result in sig-
nificant suppression of tumor growth [32]. Further-
more, a correlation between the invasive activity and
the transcriptional activation of the uPA gene has
already been reported in oral tumors and cultured
OSCC cells and tumors with high levels of both uPA
and uPAR were shown to be more invasive [20,33,34].
Correspondingly, our results demonstrate that the
more invasive OSCC express more EMMPRIN and
more uPA than the dysplastic oral tissues. This was
also observed when comparing the corresponding cell
lines. This suggests that EMMPRIN levels determine
the invasive potential through the regulation of the
two proteolytic systems, MMPs and uPA; the increase
in EMMPRIN expression during progression upregu-
lates protease production and promotes greater inva-
sion. Indeed, when the less invasive DOK cells were
treated with exogenous EMMPRIN, their invasiveness
approached that of the SCC9 invasive cells.
Conclusions
Although the role of EMMPRIN in tumor growth and
metastasis has been studied in detail, the mechanisms
by which it exerts its effects in OSCC tumorogenesis are
not completely understood. Our results showing the
induction of the uPA system provide important insights
into the mechanism by which EMMPRIN contributes to
oral tumor cell invasion and progression.
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